{"nct_id":"NCT01855750","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","status_verified_date":"2025-01","start_date":"2013-09-03","start_date_type":"ACTUAL","primary_completion_date":"2018-02-26","primary_completion_date_type":"ACTUAL","completion_date":"2019-04-05","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["JNJ"]}